Piper Jaffray analyst Joshua Schimmer said GW Pharmaceuticals remains on track to potentially launch Epidiolex for Dravet Syndrome and LGS in the first half of 2018 and he sees the company's expanded access program and ongoing trials positioning the product for a "robust launch" upon approval. Retention of patients on therapy remains "exceptionally high," added the analyst, who calls GW a top mid-cap pick citing his confidence in the commercial outlook for Epidiolex and optimism about its pipeline. Schimmer keeps an Overweight rating and $147 price target on GW Pharma shares.